Investor Overview

Corporate Profile

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. Its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by market... Read more

Stock Quote

PTGX (Common Stock)
$18.99 + 0.76 (4.17%)
Exchange :NASDAQ
Volume :292,428
Today's Open$18.29
Previous Close$18.23
Data as of December 15, 2017 4:00 p.m. ET
Refresh quote

Stock Chart

Stock chart for: PTGX.O.  Currently trading at $18.99 with a 52 week high of $23.35 and a 52 week low of $8.00.

Recent Press Releases

December 14, 2017

Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors read more

December 14, 2017

Protagonist Therapeutics Announces Final Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 read more

December 04, 2017

Protagonist Therapeutics to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference read more

Upcoming Events

There are currently no events scheduled.


Investor Presentation

Data provided by Nasdaq. Minimum 15 minutes delayed.